Fluticasone Monograph: Inhaled, Intranasal and Topical Corticosteroid Safety

Evidence-informed pharmacology monograph updated 10 November 2026. For education only; use current local labeling, clinical guidance and individual assessment.

Overview and formulations

Fluticasone is a potent synthetic glucocorticoid available as different ester formulations, including fluticasone propionate and fluticasone furoate, with inhaled, intranasal and topical products. They are not interchangeable milligram-for-milligram. Inhaled corticosteroids (ICS) control airway inflammation; intranasal therapy treats allergic rhinitis; topical products address selected corticosteroid-responsive skin disease [1–3].

Glucocorticoid receptor mechanisms

Fluticasone binds intracellular glucocorticoid receptors and alters gene transcription, reducing pro-inflammatory mediators, eosinophilic inflammation, airway edema and cytokine signaling. The main benefit of inhaled therapy is prevention of airway exacerbations over time; fluticasone alone does not provide rapid bronchodilation for acute asthma symptoms. Combination products may contain separate LABA agents with additional bronchodilator activity [1].

Asthma management

ICS-containing treatment is foundational in asthma management and reduces exacerbations. Inhaler choice depends on age, severity, availability, adherence and technique. Some ICS–formoterol combinations can be used as both controller and reliever when specifically indicated by guideline and product; this does not apply automatically to fluticasone–salmeterol, because salmeterol is not used for rapid symptom relief. Rinse and spit after inhaled doses to reduce oral candidiasis and hoarseness [1].

COPD positioning: 2026 GOLD

GOLD 2026 emphasizes bronchodilator-based management of COPD and selects ICS-containing treatment based on exacerbation history, blood eosinophils and asthma features. If an ICS is indicated, LABA–LAMA–ICS triple treatment is often preferred over LABA–ICS in COPD. Regular ICS use increases pneumonia risk, especially in susceptible patients. Do not prescribe fluticasone as isolated routine COPD controller therapy without considering other bronchodilators and exacerbation risk [2].

Pharmacokinetics and major interactions

Fluticasone has extensive hepatic first-pass metabolism and is a sensitive CYP3A4 substrate; systemic exposure usually remains low with correct local dosing but increases with strong CYP3A4 inhibition. The 2026 US fluticasone propionate inhalation label says coadministration with ritonavir, ketoconazole and other strong CYP3A4 inhibitors is not recommended because of systemic corticosteroid effects, including adrenal suppression/Cushing syndrome. This is especially important with antiretrovirals containing ritonavir or cobicistat [3].

Local and systemic safety

Inhaled therapy may cause dysphonia, oropharyngeal candidiasis and cough; intranasal therapy can cause epistaxis or irritation, and prolonged topical use can cause skin atrophy, striae or local infection. High cumulative or prolonged steroid exposure can lead to adrenal suppression, cataracts/glaucoma, reduced bone density or growth effects in children. Use the lowest effective regimen, check technique and consider systemic corticosteroid burden across all routes [1,3].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report. Available from: https://goldcopd.org/2026-gold-report-and-pocket-guide/
  3. DailyMed. Fluticasone propionate inhalation aerosol: prescribing information, updated March 25, 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27a9b531-f0fd-44ee-b197-ac4b7d64b30c
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *